Cerevance is developing therapeutics that act on target proteins expressed highly selectively in brain cell types that die in disease, play a key role in the disease process, or are located in brain circuits disrupted by disease. In some cases, our NETSseq platform has revealed that a target protein is dysregulated in human disease tissue samples. We believe that advancing drugs that act on select...
cerevance.com was registered 8 years 11 months ago. It has a alexa rank of #7,929,179 in the world. It is a domain having .com extension. It is estimated worth of $ 240.00 and have a daily income of around $ 1.00. As no active threats were reported recently, cerevance.com is SAFE to browse.
Daily Unique Visitors: | 111 |
Daily Pageviews: | 222 |
Income Per Day: | $ 1.00 |
Estimated Worth: | $ 240.00 |
Google Indexed Pages: | Not Applicable |
Yahoo Indexed Pages: | Not Applicable |
Bing Indexed Pages: | Not Applicable |
Google Backlinks: | Not Applicable |
Bing Backlinks: | Not Applicable |
Alexa BackLinks: | Not Applicable |
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | Not Applicable |
WOT Trustworthiness: | Very Poor |
WOT Privacy: | Very Poor |
WOT Child Safety: | Very Poor |
Alexa Rank: | 7,929,179 |
PageSpeed Score: | 82 ON 100 |
Domain Authority: | 49 ON 100 |
Bounce Rate: | Not Applicable |
Time On Site: | Not Applicable |
Total Traffic: | No Data |
Direct Traffic: | 27.12% |
Referral Traffic: | 0% |
Search Traffic: | 72.88% |
Social Traffic: | 0% |
Mail Traffic: | 0% |
Display Traffic: | 0% |
We would like to show you a description here but the site won’t allow us.
Cerevance’s focus on identifying new drug targets for central nervous system diseases using our proprietary NETSseq platform is featured in this PM360 Magazine Magazine article,...
Ce site est dédié aux cytopénies auto-immunes de l’enfant, un ensemble de maladies auto-immunes du sang s'attaquant aux plaquettes sanguines (PTI/Purpura Thrombopénique...
Apr 14, 2020 · BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B...
COMPANY OVERVIEW Cerevance is a new pharmaceutical company focused on central nervous system diseases. Their strengths include a powerful technology platform, a pipeline of...
"Cerevance is a new pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage...
Jul 21, 2020 · BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B …
Dec 17, 2019 · Cerevance, a clinical stage biopharmaceutical company advancing new medicines for brain diseases, has formed a multi-year research alliance with Taked
Sep 28, 2020 · After announcing a $1 billion commitment to life sciences startups earlier this year, UPMC Enterprises’ Translational Sciences team makes second external investment.
Cerevance is a new pharmaceutical company focused on central nervous system diseases. Our strengths include a powerful technology platform, a pipeline of novel discovery-stage...
Cerevance is a new pharmaceutical company focused on central nervous system diseases. The Company's strengths include a powerful technology platform, a pipeline of novel...
View Cerevance , LLC (www.cerevance.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as …
Cerevance | 816 followers on LinkedIn | Cerevance. In this Technology Networks article, our CEO Brad Margus discussed using our NETSseq platform to overcome challenges in...
Cerevance General Information Description. Developer of novel therapeutics intended to advance new medicines for serious neurological diseases. The company's therapeutics...
Implementation Of MFN, Importation, And Other Mischief In 2020 As the election nears and a potential change in power of both the White House and Congress approaches, it is...
Dec 10, 2019 · Individual results of laboratory tests from hematology panels that are abnormal and clinically significant will be summarized and listed. Observed values and...
H1 Headings: | Not Applicable | H2 Headings: | 3 |
H3 Headings: | 1 | H4 Headings: | Not Applicable |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | Not Applicable | Total Images: | 3 |
Google Adsense: | Not Applicable | Google Analytics: | UA-140650904-1 |
Domain Registrar: | GoDaddy.com, LLC |
---|---|
Registration Date: | 2015-12-10 8 years 11 months 1 week ago |
Last Modified: | 2017-01-17 7 years 10 months 1 week ago |
Host | IP Address | Country | |
---|---|---|---|
ns47.domaincontrol.com | 97.74.103.24 | United States | |
ns48.domaincontrol.com | 173.201.71.24 | United States |
Host | Type | TTL | Extra |
---|---|---|---|
cerevance.com | A | 3584 |
IP: 160.153.92.197 |
cerevance.com | NS | 3600 |
Target: ns48.domaincontrol.com |
cerevance.com | NS | 3600 |
Target: ns47.domaincontrol.com |
cerevance.com | SOA | 600 |
MNAME: ns47.domaincontrol.com RNAME: dns.jomax.net Serial: 2019052302 Refresh: 28800 Retry: 7200 Expire: 604800 |
cerevance.com | MX | 3600 |
Target: cerevance-com.mail.protection.outlook.com |
cerevance.com | TXT | 3600 |
TXT: v=spf1 include:spf.protection.outlook.com -all |
cerevance.com | TXT | 3600 |
TXT: _globalsign-domain-verification=KFDijCU3 AjMN1tb2i-7xKdWYqypa-pDKOtCBn5iv0S |
cerevance.com | TXT | 3600 |
TXT: _globalsign-domain-verification=_vg-xCoP 9IzHLWD-iDqauWKeIGp7EkBnz1ykmFoRhY |
1. | cerevance |
2. | envoy therapeutics |
3. | cerevance pipeline |
Not Applicable |
Marlowe caters to tech connoisseurs, spirited entrepreneurs, and young professionals seeking a live-work-play balance in one of Seattle’s most desirable neighborhoods.
Patient to Patient Care and support for Adrenal Fatigue ~ Hypothyroidism ~ Hashimoto's ~ Gut Health
Primada 寶康達 自煮健康入廚樂 廚房家電 智能煲 養生機 烤焗寶 慢磨機 陶燒寶 生活家電 無線旋風吸塵機